M
Michel Roger
Researcher at Université de Montréal
Publications - 162
Citations - 6919
Michel Roger is an academic researcher from Université de Montréal. The author has contributed to research in topics: Population & Human leukocyte antigen. The author has an hindex of 39, co-authored 154 publications receiving 5973 citations. Previous affiliations of Michel Roger include Jewish General Hospital.
Papers
More filters
Journal ArticleDOI
High Rates of Forward Transmission Events after Acute/Early HIV-1 Infection
Bluma G. Brenner,Michel Roger,Jean-Pierre Routy,Daniela Moisi,Michel Ntemgwa,Claudine Matte,Jean-Guy Baril,Réjean Thomas,Danielle Rouleau,Julie Bruneau,Roger LeBlanc,Mario Legault,Cécile Tremblay,Hugues Charest,Mark A. Wainberg +14 more
TL;DR: Early infection accounts for approximately half of onward transmissions in this urban North American study, suggesting therapy at early stages of disease may prevent onward HIV transmission.
Journal Article
High rates of forward transmission events after acute/early HIV-1 infection. Commentary
Deenan Pillay,Martin Fisher,Bluma G. Brenner,Michel Roger,Jean-Pierre Routy,Daniela Moisi,Michel Ntemgwa,Claudine Matte,Jean-Guy Baril,Réjean Thomas,Danielle Rouleau,Julie Bruneau,Roger LeBlanc,Mario Legault,Cécile Tremblay,Hugues Charest,Mark A. Wainberg +16 more
TL;DR: In this article, a population-based phylogenetic approach was used to characterize human immunodeficiency virus (HIV)-transmission dynamics in Quebec, where early infection accounts for approximately half of onward transmissions in this urban North American study.
Journal ArticleDOI
Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association
Eduardo Antônio Donadi,Erick C. Castelli,Antonio Arnaiz-Villena,Michel Roger,Diego Rey,Philippe Moreau +5 more
TL;DR: The understanding of gene regulation and the role of polymorphic sites on gene function may permit an individualized approach for the future use of HLA-G for therapeutic purposes.
Journal ArticleDOI
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
Bluma G. Brenner,Dan Turner,Maureen Oliveira,Daniela Moisi,Mervi Detorio,Mauricio Carobene,Richard Marlink,Jonathan M. Schapiro,Michel Roger,Mark A. Wainberg +9 more
TL;DR: V106M may be a signature mutation in clade C patients treated with EFV and may have the potential to confer high-level multi-NNRTI resistance.
Journal ArticleDOI
Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike.
Jérémie Prévost,Romain Gasser,Guillaume Beaudoin-Bussières,Jonathan Richard,Ralf Duerr,Annemarie Laumaea,Sai Priya Anand,Guillaume Goyette,Mehdi Benlarbi,Shilei Ding,Halima Medjahed,Antoine Lewin,Josée Perreault,Tony Tremblay,Gabrielle Gendron-Lepage,Nicolas Gauthier,Marc Carrier,Diane Marcoux,Alain Piché,Myriam Lavoie,Alexandre Benoit,Vilayvong Loungnarath,Gino Brochu,Elie Haddad,Hannah D. Stacey,Matthew S. Miller,Marc Desforges,Pierre J. Talbot,Graham T. Gould Maule,Marceline Côté,Christian Therrien,Bouchra Serhir,Renée Bazin,Michel Roger,Andrés Finzi,Andrés Finzi +35 more
TL;DR: While most of individuals develop neutralizing antibodies within two weeks of infection, the level ofneutralizing activity is significantly decreased over time, highlighting the importance of studying the persistence of neutralizing activity upon natural SARS-CoV-2 infection.